In the past week, CLBT stock has gone up by 4.45%, with a monthly gain of 16.55% and a quarterly surge of 39.09%. The volatility ratio for the week is 4.61%, and the volatility levels for the last 30 days are 3.71% for Cellebrite DI Ltd The simple moving average for the last 20 days is 8.91% for CLBT’s stock, with a simple moving average of 55.29% for the last 200 days.
Is It Worth Investing in Cellebrite DI Ltd (NASDAQ: CLBT) Right Now?
Moreover, the 36-month beta value for CLBT is 1.47. Analysts have varying opinions on the stock, with 6 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for CLBT is 86.01M and currently, short sellers hold a 1.32% of that float. On February 04, 2025, CLBT’s average trading volume was 1.49M shares.
CLBT) stock’s latest price update
Cellebrite DI Ltd (NASDAQ: CLBT) has experienced a rise in its stock price by 2.33 compared to its previous closing price of 24.67. However, the company has seen a gain of 4.45% in its stock price over the last five trading days. seekingalpha.com reported 2025-02-04 that Cellebrite DI LTD (CLBT) offers unique digital investigative solutions to governmental agencies, showing strong market position and 172% stock growth in the past year. CLBT’s ambitious financial targets include 24% CAGR in ARR and 20% CAGR in total revenues by 2028, with significant margin improvements since 2022. Despite a potential short-term sell-off, CLBT’s low short interest and international customer base, especially in high-growth markets, mitigate long-term risks.
Analysts’ Opinion of CLBT
Many brokerage firms have already submitted their reports for CLBT stocks, with Needham repeating the rating for CLBT by listing it as a “Buy.” The predicted price for CLBT in the upcoming period, according to Needham is $13.50 based on the research report published on March 28, 2024 of the previous year 2024.
BofA Securities gave a rating of “Buy” to CLBT, setting the target price at $12 in the report published on February 16th of the previous year.
CLBT Trading at 15.97% from the 50-Day Moving Average
After a stumble in the market that brought CLBT to its low price for the period of the last 52 weeks, the company was able to rebound, for now settling with 1.43% of gains for the given period.
Volatility was left at 3.71%, however, over the last 30 days, the volatility rate increased by 4.61%, as shares surge +14.28% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +34.62% upper at present.
During the last 5 trading sessions, CLBT rose by +4.49%, which changed the moving average for the period of 200-days by +143.30% in comparison to the 20-day moving average, which settled at $23.18. In addition, Cellebrite DI Ltd saw 14.59% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CLBT starting from YOSEF CARMIL, who proposed sale 200,000 shares at the price of $22.28 back on Jan 15 ’25. After this action, YOSEF CARMIL now owns shares of Cellebrite DI Ltd, valued at $4,456,000 using the latest closing price.
DAVID GEE, the OFFICER of Cellebrite DI Ltd, proposed sale 4,263 shares at $22.51 during a trade that took place back on Dec 27 ’24, which means that DAVID GEE is holding shares at $95,960 based on the most recent closing price.
Stock Fundamentals for CLBT
Current profitability levels for the company are sitting at:
- 0.15 for the present operating margin
- 0.84 for the gross margin
The net margin for Cellebrite DI Ltd stands at -0.82. The total capital return value is set at 0.16. Equity return is now at value -188.50, with -57.30 for asset returns.
Based on Cellebrite DI Ltd (CLBT), the company’s capital structure generated 0.04 points at debt to capital in total, while cash flow to debt ratio is standing at 8.97. The debt to equity ratio resting at 0.04. The interest coverage ratio of the stock is 0.17.
Currently, EBITDA for the company is -64.8 million with net debt to EBITDA at 2.96. When we switch over and look at the enterprise to sales, we see a ratio of 13.3. The receivables turnover for the company is 4.11for trailing twelve months and the total asset turnover is 0.61. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.81.
Conclusion
To wrap up, the performance of Cellebrite DI Ltd (CLBT) has been better in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
